Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660530 · ClinicalTrials.gov registry record · Phase 2
Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00660530 is a Phase 2 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 11 participants.
The verdict
NCT00660530, a Phase 2 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Patients with end-stage renal disease (ESRD) commonly develop hyperphosphatemia due to the loss of excretory function of the kidney. This in turn may lead to the development of secondary hyperparathyroidism (SHPT) and renal osteodystrophy. Lanthanum carbonate, a phosphate binding agent, works by releasing lanthanum ions in the gastrointestinal tract to bind dietary phosphate and is effective in the management of hyperphosphatemia and in preventing secondary hyperparathyroidism. Patients taking lanthanum carbonate as part of their phosphate binder therapy are counseled to chew the tablets completely before swallowing, with or immediately after meals. However, ESRD patients who are intubated or are receiving enteral tube feedings are unable to chew the lanthanum carbonate tablets. For such patients, medications are commonly crushed and administered through a gastrostomy tube (G-tube). Some patients may also prefer to crush the lanthanum carbonate tablets and mix it with food instead of chewing. To date, it is not known if crushing the lanthanum carbonate tablets prior to administration and taking it with food will be as efficacious as chewing it. The objective of this study is to compare the efficacy of phosphate binding between chewed and crushed lanthanum carbonate in patients undergoing hemodialysis.
Interventions
- DRUG Lanthanum Carbonate Chewable Product
- DRUG Lanthanum carbonate crushed powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660530
The ClinicalTrials.gov registry entry for NCT00660530 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lanthanum Carbonate Chewable Product is the first listed.
NCT00660530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00660530 about?
NCT00660530 is a clinical study titled "Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients". Patients with end-stage renal disease (ESRD) commonly develop hyperphosphatemia due to the loss of excretory function of the kidney. This in turn may lead to the development of secondary hyperparathyroidism (SHPT) and renal osteodystrophy. Lanthanum carbonate, a phosphate binding agent, works by rel...
What is the current status of trial NCT00660530?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2008-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00660530?
The interventions under investigation include: Lanthanum Carbonate Chewable Product (DRUG), Lanthanum carbonate crushed powder (DRUG).
Who is sponsoring clinical trial NCT00660530?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.